scholarly journals Lipopolysaccharide-Binding Protein: A New Biomarker for Infectious Endocarditis?

2009 ◽  
Vol 55 (2) ◽  
pp. 295-304 ◽  
Author(s):  
Tanja Vollmer ◽  
Cornelia Piper ◽  
Knut Kleesiek ◽  
Jens Dreier
Keyword(s):  
Binding Protein ◽  
Molecular Genetic ◽  
Protein A ◽  
Response To Therapy ◽  
Infectious Endocarditis ◽  
Therapeutic Monitoring ◽  
Lipopolysaccharide Binding Protein ◽  
Reactive Protein ◽  
Wbc Count ◽  
Lipopolysaccharide Binding

Abstract Background: Infectious endocarditis (IE) is a bacterial infection of the endocardium. Diagnosis is based on results obtained from echocardiography, blood cultures, and molecular genetic screening for bacteria and on data for inflammatory markers such as the leukocyte (WBC) count and the C-reactive protein (CRP) concentration. The aim of the present study was to evaluate lipopolysaccharide-binding protein (LBP) as a supportive biomarker for the diagnosis and therapeutic monitoring of IE. Methods: We measured LBP and CRP concentrations and WBC counts in 57 IE patients at hospital admission, 40 patients with noninfectious heart valve diseases (HVDs), and 55 healthy blood donors. The progression of these 3 markers and the influence of cardiac surgery on them were evaluated in 29 IE patients and 21 control patients. Results: Serum LBP concentrations were significantly higher in IE patients [mean (SD), 33.41 (32.10) mg/L] compared with HVD patients [6.67 (1.82) mg/L, P < 0.0001] and healthy control individuals [5.61 (1.20) mg/L]. The progression in the LBP concentration during therapy of IE patients correlated with the changes in the CRP concentration. The 2 markers were equally influenced by antibiotic treatment and surgical intervention. Conclusions: Serial LBP measurement may provide an effective and useful tool for evaluating the response to therapy in IE patients. We found a strong correlation between LBP and CRP concentrations; LBP has a tendency to increase earlier in cases of reinfection.

Old and new findings on lipopolysaccharide-binding protein: a soluble pattern-recognition molecule

2011 ◽  
Vol 39 (4) ◽  
pp. 989-993 ◽  
Author(s):  
Ralf R. Schumann
Keyword(s):  
Binding Protein ◽  
Protein A ◽  
Lipopolysaccharide Binding Protein ◽  
New Findings ◽  
Substantial Progress ◽  
Large Protein Family ◽  
Functional Consequences ◽  
Health And Disease ◽  
Lipopolysaccharide Binding ◽  
Key Questions

LBP [LPS (lipopolysaccharide)-binding protein] was discovered approximately 25 years ago. Since then, substantial progress has been made towards our understanding of its function in health and disease. Furthermore, the discovery of a large protein family sharing functional and structural attributes has helped in our knowledge. Still, key questions are unresolved, and here an overview on the old and new findings on LBP is given. LBP is an acute-phase protein of the liver, but is also synthesized in other cells of the organism. While LBP is named after the ability to bind to LPS of Gram-negative bacteria, it also can recognize other bacterial compounds, such as lipopeptides. It has been shown that LBP is needed to combat infections; however, the main mechanism of action is still not clear. New findings on natural genetic variations of LBP leading to functional consequences may help in further elucidating the mechanism of LBP and its role in innate immunity and disease.

Is lipopolysaccharide-binding protein a useful marker for systemic infection on the ICU?

2001 ◽  
Vol 18 (Supplement 21) ◽  
pp. 119-120
Author(s):  
A. Nierhaus ◽  
B. Montag ◽  
D. Frings ◽  
N. Suerhoff ◽  
J. Schulte am Esch
Keyword(s):  
Binding Protein ◽  
Protein A ◽  
Systemic Infection ◽  
Lipopolysaccharide Binding Protein ◽  
Lipopolysaccharide Binding

scholarly journals The Use of Selective Hemosorption of Lipopolysaccharides in the Complex Treatment of Sepsis

2020 ◽  
Vol 9 (2) ◽  
pp. 201-209
Author(s):  
G. V. Bulava ◽  
S. I. Rey ◽  
G. A. Berdnikov ◽  
O. V. Nikitina ◽  
A. K. Shabanov ◽  
...  
Keyword(s):  
Interleukin 6 ◽  
Binding Protein ◽  
Polymyxin B ◽  
Interleukin 10 ◽  
C Reactive Protein ◽  
Lipopolysaccharide Binding Protein ◽  
Reactive Protein ◽  
Endotoxin Activity ◽  
Blood Cytokines ◽  
Lipopolysaccharide Binding

Background Sepsis and septic shock are formidable and complications in surgery with mortality 20–50%. In the pathogenesis of sepsis, a significant role belongs to bacterial endotoxin (LPS - liposaccharide).Aim of study Assessment of the efficacy of selective lipopolysaccharides hemosorption (SLH) in treatment of sepsis.Material and methods We examined 65 patients with developed sepsis or suspected presence of gram-negative infection. Patients were retrospectively divided into two groups. In Group 1, 27 patients received Polymyxin B hemoperfusion using Toraymyxin cartridges. In Group 2 (38 patients), adsorber Alteco (LPSA) was used.Results It was established that 28-day mortality was 11.1% in Polymyxin group and 28.9% in LPS group A, p = 0.091, 60-day mortality was 33.3 and 55.3%, respectively (p=0.065). The use of SLH contributed to a decrease in the activity of endotoxin (EAA) from 0.52 (0.39; 0.65) to 0.40 (0.36; 0.57) EU (p=0.330) in Polymyxin group and from 0.59 ( 0.42; 0.72) to 0.54 (0.40; 0.81) EU ( p = 0.981) in the LPS-A group. At the same time, the level of procalcitonin (PCT) in the blood statistically significantly decreased from 8.4 (3.6; 29.0) to 4.8 (1.9; 36.3) ng/ml (p=0.0117) only in the LPS-A group. The level of C-reactive protein (CRB) in the blood statistically significantly decreased only in the Polymyxin group, from 205 (154; 264) to 162 (106; 202) mg/L (p<0.001). After SPH procedures, there was a tendency to a decrease in the level of blood cytokines in both groups. Conclusion 1. The trend of better survival among patients was noted during hemoperfusion when using Polymyxin B in comparison with the results of adsorption of lipopolysaccharide with Alteco cartridges: so, 28-day mortality was 11.1 and 28.9%, respectively (statistically not significant).2. As a result, the procedure of selective lipopolysaccharides hemosorbtion on hemosorbents with Polymyxin B in blood significantly decreased level of C-reactive protein (21%), there was statistically insignificant decrease in the level of endotoxin activity (23.1%), lipopolysaccharide binding protein (21.6%), procalcitonin (2.4 times), presepsin (20%), as well as the level of interleukin-6 (3.4 times) and interleukin-10 (1.6 times) . Adsorption of lipopolysaccharide with Alteco cartridges leads to a statistically significant reduction of procalcitonin in blood (1.8 times), and statistically insignificant decrease of: endotoxin activity (9.3%), lipopolysaccharide binding protein (28.6%), interleukin-6 (3.8 times), interleukin-10 (7.1 times) and soluble receptor to interleukin-2 (2.2 times).

Sign in / Sign up

Export Citation Format

Share Document